Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Benecyte Inc.
Durham, North Carolina, United States of Americabenecyte.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Benecyte’s lead asset, CMN‑005, a CAR-CIK CD19 therapy, has advanced to Phase II clinical trials for follicular lymphoma and splenic marginal zone B-cell lymphoma. The company also develops additional immunotherapies targeting both hematologic cancers and solid tumors using its proprietary allogeneic CIK platform.[2][4]
- Therapeutic areas
- Oncology
- Modalities
- Allogeneic cytokine-induced killer (CIK) cells[2][3]Autologous RNA-loaded dendritic cells[2]CAR-CIK cell therapies (including CARCIK-CD19)[2]
- Industry
- Biotech
Beyond the preview
Go deeper on Benecyte Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Benecyte Inc..